Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2B type 1-B (H2BC3) is a core component of the nucleosome, the fundamental unit of chromatin in eukaryotic cells. It is a basic nuclear protein that, together with other histone proteins (H2A, H3, and H4), forms the nucleosome octamer around which DNA is wrapped, enabling condensation and organization of DNA within the nucleus. H2BC3 is involved in essential biological processes such as transcription regulation, DNA replication, DNA repair, and maintenance of chromosomal stability. Post-translational modifications of H2BC3, such as acetylation, phosphorylation, and ubiquitination, play a central role in regulating chromatin structure and gene expression. Variants and modifications of H2B are implicated in processes including the DNA damage response and regulation of active transcription, while alterations or mutations in histones have been associated with diseases such as cancer and certain genetic syndromes[1][2][5]. No approved or investigational drugs currently target H2BC3 directly, and it is generally not considered a therapeutic target due to its essential and ubiquitous structural role in all nucleated cells[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2B type 1-B (H2BC3).